COVID-19 CT image segmentation method based on swin transformer.

Owing to its significant contagion and mutation, the new crown pneumonia epidemic has caused more than 520 million infections worldwide and has brought irreversible effects on the society. Computed tomography (CT) images can clearly demonstrate lung lesions of patients. This study used deep learning techniques to assist doctors in the screening and quantitative analysis of this disease. Consequently, this study will help to improve the diagnostic efficiency and reduce the risk of infection. In this study, we propose a new method to improve U-Net for lesion segmentation in the chest CT images of COVID-19 patients. 750 annotated chest CT images of 150 patients diagnosed with COVID-19 were selected to classify, identify, and segment the background area, lung area, ground glass opacity, and lung parenchyma. First, to address the problem of a loss of lesion detail during down sampling, we replaced part of the convolution operation with atrous convolution in the encoder structure of the segmentation network and employed convolutional block attention module (CBAM) to enhance the weighting of important feature information. Second, the Swin Transformer structure is introduced in the last layer of the encoder to reduce the number of parameters and improve network performance. We used the CC-CCII lesion segmentation dataset for training and validation of the model effectiveness. The results of ablation experiments demonstrate that this method achieved significant performance gain, in which the mean pixel accuracy is 87.62%, mean intersection over union is 80.6%, and dice similarity coefficient is 88.27%. Further, we verified that this model achieved superior performance in comparison to other models. Thus, the method proposed herein can better assist doctors in evaluating and analyzing the condition of COVID-19 patients.

SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative pathogen for the coronavirus disease 2019 (COVID-19) pandemic, has greatly stressed our healthcare system. In addition to severe respiratory and systematic symptoms, several comorbidities increase the risk of fatal disease outcomes, including chronic viral infections. Increasing cases of lytic reactivation of human herpesviruses in COVID-19 patients and vaccinated people have been reported recently. SARS-CoV2 coinfection, COVID-19 treatments, and vaccination may aggravate those herpesvirus-associated diseases by reactivating the viruses in latently infected host cells. In this review, we summarize recent clinical findings and limited mechanistic studies regarding the relationship between SARS-CoV-2 and different human herpesviruses that suggest an ongoing potential threat to human health in the postpandemic era.

The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.

Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways.

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.